Phase
Condition
Breast Cancer
Bone Density
Cancer
Treatment
N/AClinical Study ID
Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Stage I-IIIa breast cancer
Postmenopausal or recently postmenopausal
Recent surgery for breast cancer
Estrogen Receptor positive and/or progesterone receptor positive hormone receptorstatus
No prior treatment with letrozole Other protocol-defined inclusion criteria may apply.
Exclusion
Exclusion Criteria:
Metastatic disease
Invasive bilateral disease
Clinical or radiological evidence of existing fracture in spine or hip
Prior treatment with IV bisphosphonates in the past 12 months
Current treatment with oral bisphosphonates ( must be discontinued within 3 weeks ofbaseline evaluation)
Use of Tibolone within 6 months
Prior use of parathyroid hormone for more than 1 week
Previous or concomitant malignancy
Abnormal renal function
History of disease effecting bone metabolism Other protocol-defined exclusion criteria may apply.
Study Design
Connect with a study center
Novartis Investigative Site
Buenos Aires,
ArgentinaSite Not Available
Novartis Investigative Site
Rosario Santa Fe,
ArgentinaSite Not Available
Novartis Investigative Site
New South Wales,
AustraliaSite Not Available
Novartis Investigative Site
Perth,
AustraliaSite Not Available
Novartis Investigative Site
South Australia,
AustraliaSite Not Available
Novartis Investigative Site
Victoria,
AustraliaSite Not Available
Novartis Investigative Site
Bonheiden,
BelgiumSite Not Available
Novartis Investigative Site
Brasschaat,
BelgiumSite Not Available
Novartis Investigative Site
Brussels,
BelgiumSite Not Available
Novartis Investigative Site
Leuven,
BelgiumSite Not Available
Novartis Investigative Site
Wilrijk,
BelgiumSite Not Available
Novartis Investigative Site
Porto Alegre,
BrazilSite Not Available
Novartis Investigative Site
Sao Paulo,
BrazilSite Not Available
Novartis Investigative Site
Santiago,
ChileSite Not Available
Novartis Investigative Site
Beijing,
ChinaSite Not Available
Novartis Investigative Site
Shanghai,
ChinaSite Not Available
Novartis Investigative Site
Medellin,
ColombiaSite Not Available
Novartis Investigative Site
Nemocnice,
Czech RepublicSite Not Available
Novartis Investigative Site
Cairo,
EgyptSite Not Available
Novartis Investigative Site
Pori,
FinlandSite Not Available
Novartis Investigative Site
Turku,
FinlandSite Not Available
Novartis Investigative Site
Bordeaux Cedex,
FranceSite Not Available
Novartis Investigative Site
Le Havre,
FranceSite Not Available
Novartis Investigative Site
Montpellier Cedex,
FranceSite Not Available
Novartis Investigative Site
Poitiers Cedex,
FranceSite Not Available
Novartis Investigative Site
St. Cloud,
FranceSite Not Available
Novartis Investigative Site
Augsberg,
GermanySite Not Available
Novartis Investigative Site
Berlin,
GermanySite Not Available
Novartis Investigative Site
Ebersberg,
GermanySite Not Available
Novartis Investigative Site
Frankfurt,
GermanySite Not Available
Novartis Investigative Site
Halberstadt,
GermanySite Not Available
Novartis Investigative Site
Hamburg,
GermanySite Not Available
Novartis Investigative Site
Hoyerswerda,
GermanySite Not Available
Novartis Investigative Site
Kassel,
GermanySite Not Available
Novartis Investigative Site
Kiel,
GermanySite Not Available
Novartis Investigative Site
Muenchen,
GermanySite Not Available
Novartis Investigative Site
Munich,
GermanySite Not Available
Novartis Investigative Site
Neunkirchen,
GermanySite Not Available
Novartis Investigative Site
Rostock,
GermanySite Not Available
Novartis Investigative Site
Stadthagen,
GermanySite Not Available
Novartis Investigative Site
Stendal,
GermanySite Not Available
Novartis Investigative Site
Trier,
GermanySite Not Available
Novartis Investigative Site
Tubingen,
GermanySite Not Available
Novartis Investigative Site
Wiesbaden,
GermanySite Not Available
Novartis Investigative Site
Guatemala City,
GuatemalaSite Not Available
Novartis Investigative Site
Hong Kong,
Hong KongSite Not Available
Novartis Investigative Site
Ancona,
ItalySite Not Available
Novartis Investigative Site
Aviano, 33081
ItalySite Not Available
Novartis Investigative Site
Bergamo,
ItalySite Not Available
Novartis Investigative Site
Catanzaro, 88100
ItalySite Not Available
Novartis Investigative Site
Firenze, 50139
ItalySite Not Available
Novartis Investigative Site
Genova,
ItalySite Not Available
Novartis Investigative Site
Meldola,
ItalySite Not Available
Novartis Investigative Site
Modena,
ItalySite Not Available
Novartis Investigative Site
Orbassano Torino,
ItalySite Not Available
Novartis Investigative Site
Perugia,
ItalySite Not Available
Novartis Investigative Site
Torino,
ItalySite Not Available
Novartis Investigative Site
Varese,
ItalySite Not Available
Novartis Investigative Site
Gyeonggi,
Korea, Republic ofSite Not Available
Novartis Investigative Site
Seoul, 139
Korea, Republic ofSite Not Available
Novartis Investigative Site
Distrito Federal,
MexicoSite Not Available
Novartis Investigative Site
Almere,
NetherlandsSite Not Available
Novartis Investigative Site
Arnhem,
NetherlandsSite Not Available
Novartis Investigative Site
Den Haag,
NetherlandsSite Not Available
Novartis Investigative Site
Ede,
NetherlandsSite Not Available
Novartis Investigative Site
Eindhoven,
NetherlandsSite Not Available
Novartis Investigative Site
Hoogeveen,
NetherlandsSite Not Available
Novartis Investigative Site
Leiden,
NetherlandsSite Not Available
Novartis Investigative Site
Nijmegen,
NetherlandsSite Not Available
Novartis Investigative Site
Utrecht,
NetherlandsSite Not Available
Novartis Investigative Site
Hamilton,
New ZealandSite Not Available
Novartis Investigative Site
Wellington,
New ZealandSite Not Available
Novartis Investigative Site
Jesus Maria,
PeruSite Not Available
Novartis Investigative Site
La Victoria,
PeruSite Not Available
Novartis Investigative Site
Surquillo,
PeruSite Not Available
Novartis Investigative Site
Cebu City,
PhilippinesSite Not Available
Novartis Investigative Site
Quezon City,
PhilippinesSite Not Available
Novartis Investigative Site
Coimbra,
PortugalSite Not Available
Novartis Investigative Site
Barcelona,
SpainSite Not Available
Novartis Investigative Site
Cordoba,
SpainSite Not Available
Novartis Investigative Site
Gea,
SpainSite Not Available
Novartis Investigative Site
Ibanez,
SpainSite Not Available
Novartis Investigative Site
La Maso,
SpainSite Not Available
Novartis Investigative Site
Villaroel,
SpainSite Not Available
Novartis Investigative Site
Bern,
SwitzerlandSite Not Available
Novartis Investigative Site
Locarno,
SwitzerlandSite Not Available
Novartis Investigative Site
Lugano,
SwitzerlandSite Not Available
Novartis Investigative Site
Chang Hwa, 500
TaiwanSite Not Available
Novartis Investigative Site
Taipei, 100
TaiwanSite Not Available
Novartis Investigative Site
Bangkok,
ThailandSite Not Available
Ratchathew
Khonkaen, 40002
ThailandSite Not Available
Novartis Investigative Site
Birmingham,
United KingdomSite Not Available
Novartis Investigative Site
Essex,
United KingdomSite Not Available
Novartis Investigative Site
Manchester,
United KingdomSite Not Available
Novartis Investigative Site
New Castle Upon Tyne,
United KingdomSite Not Available
Novartis Investigative Site
Nottingham,
United KingdomSite Not Available
Novartis Investigative Site
Plymouth,
United KingdomSite Not Available
Novartis Investigative Site
Sheffield,
United KingdomSite Not Available
Novartis Investigative Site
Swansea,
United KingdomSite Not Available
Novartis Investigative Site
Caracas,
VenezuelaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.